TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All participants will be patients who receive their primary medical care at the Virginia Garcia Memorial Health Center (VGMHC)~* Self-identified as Spanish-speaking Latina or Hispanic~* Female~* Age 18 and older~* BMI greater than or equal to 27kg/m2~* Classified as diabetic or prediabetic in the electronic medical record by at least one of the following:~  * Fasting plasma glucose ≥ 100~ * 2-h post glucose level on the 75-g oral glucose tolerance test ≥ 140-199 mg/dL (7.8-11.0 mmol/L)~ * Hemoglobin HBA1c ≥ 5.7~ * Diagnosis of diabetes in patient's medical chart~ * Diagnosis of prediabetes in patient's medical chart~* Residing in the Portland metropolitan area, and having no plans to leave the area in the next 18 months.~* Willing and able to attend the 26-weekly group meetings and 6 monthly group meetings.~* Willing to accept random assignment to the active intervention or enhanced usual care control.~* Clearance by the patient's VGMHC primary care physician to participate in the intervention.~Exclusion Criteria:~* Treatment for cancer in the past two years (excluding non-melanoma skin cancers).~* Having conditions that require limitation of physical activity or that would be contraindicated for the DASH (Dietary Approaches to Stop Hypertension) diet patterns.~* Taking weight-loss medication currently or within the past 6 months.~* Current or recent (\< 12 months) pregnancy, breastfeeding, or planning pregnancy in the next 18 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Behavioral (Type: EXPERIMENTAL): 26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
- Enhanced usual care (Type: NO_INTERVENTION): Printed materials

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Caucasian;~2. Male sex;~3. Age: 18-30~4. BMI: 18-25 kg/m2;~5. Normal physical activity levels;~Exclusion Criteria:~1. Not meeting all inclusion criteria~2. Cardiovascular diseases (determined by means of questionnaires, heart rate/blood pressure measurements)~3. Respiratory diseases (including asthma, bronchitis and COPD);~4. Unstable body weight (weight gain or loss \> 5 kg in the last three months);~5. Intention to lose or gain body weight (e.g. with caloric restriction or physical activity)~6. Excessive alcohol and/or drug abuse;~7. Hypokalaemia;~8. Hb \< 8.4 mmol/L;~9. Epilepsy;~10. Smoking;~11. Renal and/or liver insufficiency;~12. Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results;~13. Medication use known to hamper subject's safety during the study procedures;~14. Subjects who do not want to be informed about unexpected medical findings;~15. Subjects who do not want that their treating physician to be informed;~16. Inability to participate and/or complete the required measurements;~17. Participation in organised or structured physical exercise;~18. Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk;~19. Hyperthyroidism

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Clenbuterol hydrochloride (Type: EXPERIMENTAL): Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period.
- Placebos (Type: PLACEBO_COMPARATOR): Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO) classification~* Low or Intermediate-1 risk category MDS using the IPSS~* Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each cycle for at least 4 cycles~* Eastern Cooperative Oncology (ECOG) performance status of 0-2~* Subjects must be at least 18 years of age or older~Exclusion Criteria:~* Prior exposure to \>3 cycles of lenalidomide~* Exposure to lenalidomide within the last 30 days~* Prior history of leukemia or aplastic anemia~* Prior history of stem cell transplantation~* Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for 3 years before randomization~* Active or uncontrolled infections~* Unstable angina, congestive heart failure \[NYHA \> class II\], uncontrolled hypertension \[diastolic \> 100 mmHg\], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction~* History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past year~* History of venous thrombosis in the past year~* Received IL-11 within 4 weeks of screening~* Less than 4 weeks since receipt of any investigational drug or device~* Have previously received any other thrombopoietic growth factor~* Pregnant or breast feeding~* Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator~* Known hypersensitivity to any recombinant E coli-derived product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 750 mcg AMG 531 (Type: ACTIVE_COMPARATOR): 750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- Placebo Part B (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
- Placebo Part A (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- 500 mcg AMG 531 (Type: ACTIVE_COMPARATOR): 500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- 750 mcg AMG531 Part B (Type: ACTIVE_COMPARATOR): 750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) according to the current WHO classification, including all morphological variants~  * Newly diagnosed disease~ * Bulky stage IA-IV disease~    * No non-bulky stage IA disease~* Measurable disease~* Not eligible for CHOP chemotherapy due to impaired cardiac function~  * Cardiac status that does not allow the administration of 8 courses of R-CHOP chemotherapy, as defined by 1 of the following criteria:~    * Ejection fraction less than 50% as assessed by either ECHO or MUGA scan~   * NYHA class III-IV~* No high-grade transformation of low-grade lymphoma~* No symptomatic central nervous system or meningeal involvement by the lymphoma~* No AIDS-related lymphoma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 3 months~* Platelet count \> 100 x 10\^9/L~* WBC \> 3 x 10\^9/L~* Neutrophils \> 1.5 x 10\^9/L (unless elevated level attributed to bone marrow infiltration by lymphoma)~* Serum bilirubin \< 50 μmol/L~* Transaminases \< 2.5 times upper limit of normal (unless elevated level attributed to lymphoma)~* Glomerular filtration rate \> 30 mL/min~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other concurrent uncontrolled medical condition~* No active malignant disease, other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix, within the past 10 years~* No positive serology for HIV~* No medical or psychiatric conditions that compromise the patient's ability to give informed consent~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, radiotherapy, or other investigational drug for this indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-GCVP (Type: EXPERIMENTAL): Up to 6 x 21 day cycles of R-GCVP:~* Gemcitabine 750mg/m\^2 days 1 \& 8 (increasing to 875mg/m\^2 for cycle 2 \& 1g/m\^2 for subsequent cycles if tolerated satisfactorily)~* Cyclophosphamide 750mg/m\^2 day 1~* Vincristine 1.4mg/m\^2 day 1 (capped at 2mg)~* Prednisolone 100mg/day days 1-5~* Rituximab 375mg/m\^2 day 1~* Neulasta 6mg day 9

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80 years~* Lipoprotein (a) \> 150 nmol/L~* Evidence of atherosclerotic cardiovascular disease~Exclusion Criteria:~* Severe renal dysfunction~* History or clinical evidence of hepatic dysfunction~* Malignancy within the last 5 years~* Currently receiving, or less than 3 months at Day 1 since receiving \> 200 mg/day Niacin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 Olpasiran Dose 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 Olpasiran Dose 2 (Type: ACTIVE_COMPARATOR): None
- Arm 3 Olpasiran Dose 3 (Type: ACTIVE_COMPARATOR): None
- Arm 4 Olpasiran Dose 4 (Type: ACTIVE_COMPARATOR): None
- Arm 5 Placebo Dose 5 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or above 18 years~* Male or female gender~* In case of women, unwillingness to remain pregnant during the study period.~* Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent~* Confirmed infection by SARS-CoV-2 virus using molecular techniques as defined by the World Health Organization~* Findings in chest-X-ray or in chest computed tomography compatible with lower respiratory tract infection~* Plasma suPAR ≥6ng/ml~Exclusion Criteria:~* Age below 18 years~* Denial for written informed consent~* Any stage IV malignancy~* Any do not resuscitate decision~* Any primary immunodeficiency~* Less than 1,500 neutrophils/mm3~* Known hypersensitivity to anakinra~* Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone for a greater period than the last 15 days.~* Any anti-cytokine biological treatment the last one month~* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study~* Severe hepatic failure~* Severe renal failure~* Any need for CPAP or mechanical ventilation~* Any pO2/FiO2 ratio less than 150

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be diagnosed with AOSD according to preliminary classification by Yamaguchi (1992).~* Other diseases with similar symptoms must be excluded. Has been exposed to a corticosteroid for ≥2 months prior to randomization for AOSD.~* Needs a prednisolone dose ≥10 mg/day or equivalent, yet unacceptable disease activity determined by the investigator.~* Anti-TNF agents must be discontinued 4 to 8 weeks prior to commencing study medication.~Exclusion Criteria:~* Use of corticosteroids (prednisolone equivalent \<10 mg/day.~* History of recurrent or chronic infection, including:~  * tuberculosis~ * any malignancy~ * any other major chronic inflammatory disease syndrome~ * drug or alcohol abuse~ * known positivity for hepatitis B, C or HIV.~* Use of anti-TNF agents during ≤4 weeks (etanercept) or≤8 weeks (infliximab or adalimumab) prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): experimental drug of study
- comparator (Type: ACTIVE_COMPARATOR): comparators:methotrexate, azathioprine, leflunomide or supfasalazine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Healing Touch After Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. the ability to ensure informed consent and completion of study assessments~2. the ability to speak, read, and understand English~3. scheduled cesarean delivery~4. ≥18 years of age~Exclusion Criteria:~1. Non-English speaking due to the fidelity and variability of the research~2. Prisoners~3. Isolation precautions~4. active psychosis and impaired cognition~5. cesarean delivery who delivers prior to scheduled cesarean date -

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Healing Touch (Type: EXPERIMENTAL): Subjects in this arm get a HT session post cesarean
- Control (Type: ACTIVE_COMPARATOR): Subjects in this arm get a control activity of equal duration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Handling Oxygenation Targets in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acutely admitted to the ICU AND~* Aged ≥ 18 years AND~* Receives supplemental oxygen with a flow of at least 10 L per minutes in an open system including high-flow systems OR recieves supplemental oxygen in a closed system including invasive or non-invasive ventilation or continuous positive airway pressure (CPAP)-systems AND~* Expected to receive supplemental oxygen for at least 24 hours in the ICU AND~* Having an arterial line for PaO2 monitoring AND~* Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) in the time leading to or during current hospital admission~Exclusion Criteria:~* Cannot be randomised within twelve hours after present ICU admission~* Chronic mechanical ventilation for any reason~* Use of home oxygen~* Previous treatment with bleomycin~* Organ transplant during current hospital admission~* Withdrawal from active therapy or brain death deemed imminent~* Fertile woman (\< 50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG~* Carbon monoxide poisoning~* Cyanide poisoning~* Methaemoglobinaemia~* Paraquat poisoning~* Any condition expected to involve the use of hyperbaric oxygen (HBO)~* Sickle cell disease~* Consent not obtainable according to national regulations~* Previously randomised into the HOT-COVID trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low oxygenation target (Type: EXPERIMENTAL): Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
- High oxygenation target (Type: ACTIVE_COMPARATOR): Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older with a minimum body weight of 40 kg~* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)~* Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control~Exclusion Criteria:~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with JAK inhibitors~* Other active nonAD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 100 mg QD (Type: EXPERIMENTAL): Double-blind randomized treatment following open label run-in period.
- PF-04965842 200 mg QD (Type: EXPERIMENTAL): Double-blind randomized treatment following open label run-in period.
- Placebo QD (Type: PLACEBO_COMPARATOR): Double-blind randomized treatment following open label run-in period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Not currently on drug therapy for type 2 diabetes~* Body mass index (BMI) in the range 22-45~* Diagnosis of type 2 diabetes for at least 8 weeks~Exclusion Criteria:~* Pregnancy or lactation~* Type 1 diabetes~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular complications~* Significant laboratory abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mental health providers, psychiatrist, social workers, psychologist, advanced practice nurses and case managers~Exclusion Criteria:~* Previous CAMS Training

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Intervention 1: in person CAMS (Type: EXPERIMENTAL): In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
- Intervention 2: e-learning CAMS (Type: EXPERIMENTAL): Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
- Control: no training (Type: NO_INTERVENTION): Control Group: no training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete